ANPAC BIO-MED SP.ADS/20 A
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developi… Read more
Market Cap & Net Worth: ANPAC BIO-MED SP.ADS/20 A (0UC0)
ANPAC BIO-MED SP.ADS/20 A (F:0UC0) has a market capitalization of $453.22 Million (€441.53 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #21709 globally and #2359 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANPAC BIO-MED SP.ADS/20 A's stock price €18.00 by its total outstanding shares 24529400 (24.53 Million).
ANPAC BIO-MED SP.ADS/20 A Market Cap History: 2020 to 2024
ANPAC BIO-MED SP.ADS/20 A's market capitalization history from 2020 to 2024. Data shows change from $2.19 Billion to $453.22 Million (-36.39% CAGR).
ANPAC BIO-MED SP.ADS/20 A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANPAC BIO-MED SP.ADS/20 A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0UC0 by Market Capitalization
Companies near ANPAC BIO-MED SP.ADS/20 A in the global market cap rankings as of March 18, 2026.
Key companies related to ANPAC BIO-MED SP.ADS/20 A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ANPAC BIO-MED SP.ADS/20 A Historical Marketcap From 2020 to 2024
Between 2020 and today, ANPAC BIO-MED SP.ADS/20 A's market cap moved from $2.19 Billion to $ 453.22 Million, with a yearly change of -36.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €453.22 Million | +900.00% |
| 2023 | €45.32 Million | -53.00% |
| 2022 | €96.43 Million | -86.79% |
| 2021 | €730.18 Million | -66.59% |
| 2020 | €2.19 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 27th, 2025 the market cap of ANPAC BIO-MED SP.ADS/20 A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $453.22 Million USD |
| MoneyControl | $453.22 Million USD |
| MarketWatch | $453.22 Million USD |
| marketcap.company | $453.22 Million USD |
| Reuters | $453.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.